Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves

Sundry Photography Introduction Johnson & Johnson (NYSE:JNJ), which offers a range of healthcare solutions across the globe, hasn’t done a great deal of good for its shareholders over the past year. Admittedly, even other healthcare stocks from the S&P500 (XLV) have hardly dazzled either, generating positive returns of just low single digits (on average), when the benchmark has surged by +24%. However, JNJ has fared a lot worse, by consistently underperforming XLV through the year, and eventually erodin ...